BRIEF published on 07/09/2026 at 10:05, 2 months 3 days ago Axxam and HeartBeat.bio Form Partnership for Cardiovascular Drug Innovation New Approach Methodologies Cardiovascular Drug Discovery Cardiac Safety Assessment Human Cardiac Organoids Drug Discovery Collaboration
BRIEF published on 07/09/2026 at 10:05, 2 months 3 days ago Axxam et HeartBeat.bio s'associent pour l'innovation dans le domaine des médicaments cardiovasculaires Nouvelles Méthodologies D'approche Découverte De Médicaments Cardiovasculaires Évaluation De La Sécurité Cardiaque Organoïdes Cardiaques Humains Collaboration En Matière De Découverte De Médicaments
PRESS RELEASE published on 07/09/2026 at 10:00, 2 months 3 days ago Axxam and HeartBeat.bio partner to advance human-relevant cardiovascular drug discovery and cardiac safety assessment Axxam and HeartBeat.bio form strategic partnership to enhance cardiovascular drug discovery and safety assessment with human cardiac organoid technology Partnership Axxam HeartBeat.bio Cardiovascular Drug Discovery Human Cardiac Organoid
BRIEF published on 09/23/2025 at 10:05, 11 months 19 days ago HeartBeat.bio Collaborates with Boehringer Ingelheim on Gene Therapies Cardiovascular Health Research Collaboration Gene Therapies Heart Muscle Disorders Cardioid Platform
BRIEF published on 09/23/2025 at 10:05, 11 months 19 days ago HeartBeat.bio collabore avec Boehringer Ingelheim sur les thérapies géniques Santé Cardiovasculaire Collaboration En Recherche Thérapies Géniques Troubles Du Muscle Cardiaque Plateforme Cardioïde
PRESS RELEASE published on 09/23/2025 at 10:00, 11 months 19 days ago HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders HeartBeat.bio collaborates with Boehringer Ingelheim to develop gene therapies for genetic cardiomyopathies, addressing unmet needs in heart health Heart Health Gene Therapy Boehringer Ingelheim HeartBeat.bio Cardiomyopathies
PRESS RELEASE published on 11/02/2023 at 11:00, 2 years 10 months ago HeartBeat.bio raises € 4.5 million in Pre-Series A financing to drive development of organoid screening platform for cardiac drug discovery
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
